Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 10/20 | 0.50 |
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13816844 | 0.86 | ESR2 (0.52) | ESR2ESR1 | |
| SCHEMBL5460555 | 0.77 | ESR2 (0.45) | ESR2ESR1ALDH1A1HTR2AHTR2C | |
| SCHEMBL4732373 | 0.77 | ESR2 (0.45) | ESR2ESR1ALDH1A1HTR2AHTR2C | |
| SCHEMBL4782328 | 0.77 | ESR2 (0.45) | ESR2ESR1ALDH1A1HTR2AHTR2C | |
| SCHEMBL10529811 | 0.71 | ESR2 (0.54) | ESR2ESR1MEN1ALDH1A1KMT2A | |
| SCHEMBL10658524 | 0.70 | ESR2 (0.45) | ESR2ESR1MEN1ALDH1A1KMT2A | |
| SCHEMBL11111816 | 0.68 | ESR2 (0.52) | ESR2ESR1MEN1ALDH1A1KMT2A | |
| SCHEMBL2411976 | 0.68 | ESR2 (0.53) | ESR2ESR1 | |
| SCHEMBL1657131 | 0.67 | BACE1 (0.41) | MAPK10MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL2422946 | 0.67 | ESR2 (0.73) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827421-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-1827421-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-1943224-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1943224-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| EP-1827421-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1819656-A2 | SYNTHESIS OF 1,5-DISTRIBUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007089291-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089291-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1809594-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7151196-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-12-19 | — | — | US | disclosed |
| WO-2006062876-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006050399-A2 | SYNTHESIS OF 1,5-DISUBSTITUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006050402-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094779-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094779-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ESR2 2/4885ESR1 6/4885MAPK10 736/4885 |
| US-20100168188-A1 | Estrogen Receptor Modulators | ESR2, GPER1, ESRRA | ESR2 1/4885ESR1 5/4885MAPK10 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.